Trials / Recruiting
RecruitingNCT06907628
A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors
A Phase Ⅰ, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-3792 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SHR-3792 injection monotherapy for patients with advanced solid tumors, and to explore the reasonable dosage of SHR-3792 injection monotherapy for patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3792 Injection | SHR-3792 injection. |
Timeline
- Start date
- 2025-04-02
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
- First posted
- 2025-04-02
- Last updated
- 2025-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06907628. Inclusion in this directory is not an endorsement.